However, blood is not an ideal fluid for protein production, because it collects secretions from many other non-target tissues and many proteins are poorly stable in serum. In addition, blood collection is invasive and some proteins may have serious impact on the health of the animals, which makes the system impractical [16, 17] . Bladder is an alternative system for producing foreign proteins, for urine is an abundant biological fluid which can be collected more easily and much earlier than milk. Of note, the bladder epithelium does secrete proteins, but the secretion rates are very low, which leads to extremely low protein production rates [18] [19] [20] . Ovary in hen is another ideal bioreactor, for a single hen can produce up to 330 eggs/year and egg white is also an abundant fluid naturally containing 4 g of proteins/egg [21] [22] [23] . Yet, it has not been adopted so far, because it is technically difficult to generate transgenic birds at present [24] . Vesicular gland has been reported to be a promising bioreactor, for it secretes proteins into seminal plasma [25] . Seminal plasma is a relatively abundant biological fluid in some species such as swine, and it can also be easily collected. However, to date, only seminal vesicle in male accessory sex glands has been reported to produce foreign proteins in the semen at laboratory level.
As one of the male accessory sex glands, the epididymis, which consist of two long (5-7 m), highly coiled, and narrow tubules, lie along the testes from their upper ends to lower back sides (Fig. 1) [26] . Epididymis has very strong secretion capacity and can secrete at least several hundred kinds of proteins [27, 28] . The naturally secreted proteins by epididymal epithelia are released into epididymal lumen and finally become the constituents of semen. As such, epididymis may have great potential to secrete artificial proteins into seminal plasma. Here, we hypothesize that mammalian epididymis can be used as a bioreactor to produce pharmaceutical proteins (Fig. 1) . The rationale is as follows: (i) biological and genetic background of epididymis among male accessory sex glands is relatively clear; (ii) epididymis can secrete proteins into epididymal lumen and finally into seminal plasma; (iii) proteins secreted by epididymis have various kinds of posttranslational modifications; (iv) certain proteins secreted by epididymis are in high content in semen; (v) proteins secreted by epididymal epithelial cells can be stored in and protected by the epididymosome (exosome in epididymal lumen); (vi) epididymal transgenic animals are technically feasible; (vii) proteins from semen can be easily isolated; and (viii) production of foreign proteins using epididymis may be achieved at low cost.
Collecting foreign proteins from semen was proved successful by expressing proteins in seminal vesicle [25] . But, to date, little biological and genetic background about seminal vesicle is available, which limits the application of seminal plasma for the production of pharmaceutical proteins. Note that 15 years have passed since seminal vesicle was first proposed as a foreign protein production platform in a paper published in Nature Biotechnology [25] ; but its industrial application has not been realized. Fortunately, a lot of researches have been carried out focusing on epididymal secreted proteins [27] . For example, epididymis-specific promoters have been characterized [29] and they can be used to specifically express foreign proteins in epididymis without negative impacts on other organs; various kinds of post-translational modification of epididymal secreted proteins provide enormous potential for bioactive protein production [28, [30] [31] [32] [33] [34] [35] [36] ; proteins originated from epididymis in high content in seminal plasma suggest the potential of high expression of foreign proteins [37] ; proteins secreted by epididymis may not be degraded by protein enzymes when they are secreted into the epididymosome [38] . Notably, expressing proteins in male accessory sex glands has little adverse effect on animal health. In terms of species, swine is a best candidate, because swine has large ejaculates and can be easily scaled up. Theoretically, epididymis bioreactor seems to be the best bioreactor in current transgenic animals.
In practical application, we may express human growth hormone (hGH) (or other pharmaceutical proteins) in swine by using the promoter of epididymis-specific gene Lcn5 (or other promoters) [25, 29, 39] . We can construct the Lcn5-hGH plasmid, collect swine embryos and microinject and transfer the embryos into pseudopregnant recipients. Offspring can be screened for the Lcn5-hGH transgenic swine by polymerase chain reaction or Southern blot analysis. The target protein of hGH in swine semen can be isolated by common methods [25] . In addition, for the better use of epididymis as a good bioreactor in the future, we may also clone other promoters of epididymis-specific genes such as Esp14.6, Sc-461 (Rnase 9), Sc-513 (Lcn 9), Sc-615 (Ces7), Gpx5, Esp13.2 (b-Defensin 126), and so on [28, 40] , because their expression region is wider than that of Lcn5. To speed things along for generating transgenic animals, we may try some special transgenic methods such as lentiviral transgenesis, ZFN, TALEN, and CRISPI. In addition, some physiological proteins in epididymis may be re-absorbed, but whether the re-absorption of foreign proteins in epididymis will occur still remains to be investigated.
In summary, compared with other systems, transgenic animal bioreactors represent powerful tools to meet the growing need for therapeutic proteins. Among them, the most practical, economic, and convenient transgenic animal biomanufacturing system currently available is the mammary gland. Here, we propose that epididymis, for having many advantages over mammary gland and other systems, may represent a very promising new transgenic animal bioreactor for the production of pharmaceutical proteins.
Funding
This work was supported by a grant from the National Natural Science Foundation of China (81200468). A new animal bioreactor for producing pharmaceutical proteins
